ClinicalTrials.gg
RecruitingNCT06723444Updated Feb 12, 2025

Improving Learning and Memory in Portuguese Patients With Multiple Sclerosis

An interventional study of Learning and Memory Training and Placebo Comparator in Multiple Sclerosis, sponsored by Centro Hospitalar De São João, E.P.E.. Recruiting at 1 site in Portugal. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Centro Hospitalar De São João, E.P.E. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Multiple Sclerosis with a site in Portugal — 9 open to participants now, 19 under way, 11 of them phase 3. Multiple Sclerosis · Portugal.

Planned enrollment
47th of 50
80 · median 640
Started
2024
with 2 others
No phase
3 of 64
2 open now
Primary completion
2026-12
later than 5 of 18 live
Registered
58th of 64
by date

Among the 64 studies in Multiple Sclerosis with a site in Portugal, this one is the 47th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 with no phase, reaches primary completion later than 5 of the 18 other live ones, and was the 58th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

9 of the 64 studies in Multiple Sclerosis with a site in Portugal are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Multiple Sclerosis with a site in Portugal, or all of them as a file.
02

Study summary

Deficits in memory and learning are common in Multiple Sclerosis, posing significant challenges in patients' daily lives. Cognitive rehabilitation has been shown to be effective in ameliorating these deficits, with programs such as the Modified Story Memory Technique (mSMT). In Portugal, no studies tested the efficacy of memory training programs. We aim to fill that gap by translating and developing mSMT, conducting a randomized double-blind, placebo-control, clinical trial, and, therefore, testing its efficacy through objective measures of cognitive function, and the maintenance of its benefits longitudinally. Patients with documented impairment in new learning abilities will be recruited at Centro Hospitalar Universitario São João, and randomly assigned to a memory retraining group or an active control group. Both groups will undergo baseline, immediate, and long-term follow-up assessments consisting of (1) a neuropsychological comprehensive assessment and (2) self-reported questionnaires regarding symptoms of anxiety, depression, fatigue, quality of life, and sleep. Optional enrollment in pre-post neuroimaging will also allow us to look at changes in the brain.

Read the detailed description

Cognitive impairment in Multiple Sclerosis (MS) can manifest insidiously even before other neurological symptoms, with 40% to 65% of patients experiencing deficits. Long-term memory is consistently affected, with weak initial learning tending to lead to poor retrieval. Despite being invisible, cognitive problems in MS present significant challenges, as pharmacological treatments have shown limited efficacy in improving cognitive functions. Meanwhile, cognitive rehabilitation proves beneficial and meaningful among MS patients, with optimal outcomes observed at early stages.

The modified Story Memory Technique (mSMT) aims to ameliorate learning and memory deficits and has proven to be effective throughout three realms of assessment: objective cognitive abilities, daily life functioning, and neuroimaging. Its efficacy was already tested in different populations namely MS, progressive MS only, and traumatic brain injury. The mSMT involves ten individual sessions conducted twice weekly over five weeks, incorporating techniques such as imagery, context, and generalization. In the first four sessions, participants read stories for which they must create visual imagery to aid memory - imagery. In sessions 5 to 8, participants have word lists that they embed in a story and then visualize it - context. Sessions 9 and 10 apply mSMT to real-world situations (e.g., directions, to-do lists, and shopping) - generalization. Booster sessions may also be administered to maintain treatment effects over time. Previous studies have shown that memory improvements were sustained even six months after completion, highlighting its efficacy in MS. Neuroimaging studies proved the clinical utility of this intervention with significant changes in cerebral activation in regions associated with imagery and verbal learning, results considered extremely promising for the field of neurorehabilitation. Recognizing the need for cognitive rehabilitation programs adapted to Portuguese MS patients, the main objective of this project is to develop and test the efficacy of the Portuguese version of mSMT on MS patients in a hospital setting. This will be done through a Randomized Clinical Trial (RCT) throughout three realms of assessment: behavioral, neuropsychological, and neuroimaging.

Aim 1. Test the efficacy and the clinical utility of the Portuguese version of mSMT through objective measures of cognitive function and self-reported questionnaires regarding symptoms of anxiety, depression, fatigue, quality of life, and sleep. For this purpose, we will conduct a randomized double-blind, placebo-control, clinical trial in a hospital setting.

Aim 2. Assess the efficacy of this memory retraining protocol in a mildly impaired group and a moderate to severely impaired group.

Aim 3. Examine the maintenance of treatment effects longitudinally, through the inclusion of 6-month and 18-month follow-up assessments.

Aim 4. Examine the mSMT efficacy considering variables such as the previous neuropsychological profile and neuroimaging data.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Memory
  • Cognitive Rehabilitation
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • established diagnosis of MS, according to McDonald criteria;
  • adult native Portuguese speakers;
  • at least four years of education;
  • free of exacerbations and use of for at least one month, and no neurologic history other than MS;
  • no history of major depressive disorder, schizophrenia, bipolar disorder, and no history of substance use/dependence;
  • no significant visual impairment that impacts the ability to see testing materials and language comprehension as measured by the Token Test;
  • impaired verbal new learning as documented by a performance of -1.0 or worse standard deviations below the mean, using age, sex and education-adjusted Portuguese norms on the Selective Reminding Test from the Brief Repeatable Battery of Neuropsychological Tests.

Exclusion criteria

Exclusion Criteria:

  • an exacerbation within one month;
  • neurological history of head injury, stroke, seizures, or any other significant neurological history;
  • patients on , benzodiazepines, and/or neuroleptics;
  • patients with an active diagnosis of Major Depressive Disorder, Schizophrenia, Bipolar Disorder;
  • poor visual acuity, diplopia, or nystagmus;
  • inability to understand directions and following one, two, and three step commands;
  • and intact new learning and memory.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    The intervention group will receive paper and pencil learning and memory training exercises, administered twice a week for five weeks (10 training sessions).

    Behavioral: Learning and Memory Training

  • Placebo comparator
    Placebo Control Group

    The placebo control group will receive paper and pencil placebo memory exercises administered twice a week for five weeks (10 placebo control sessions).

    Behavioral: Placebo Comparator

Interventions

  • BehavioralLearning and Memory Training

    The intervention group will receive learning and memory retraining exercises, in order to learn how to apply two techniques: imagery and context. Paper and pencil memory retraining exercises will be administered twice a week for five weeks (10 training sessions).

  • BehavioralPlacebo Comparator

    The placebo control group will receive paper and pencil placebo memory exercises, without learning techniques, administered twice a week for five weeks (10 placebo control sessions).

06

What researchers measure

Primary outcomes

  1. Verbal memory

    Selective Reminding Test from Brief Repeatable Battery of Neuropsychological Tests (BRBN-T), with higher scores mean better outcome performance.

    Time frame: Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.

  2. Verbal memory

    California Verbal Learning Test II from Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), with higher scores mean better outcome performance.

    Time frame: Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.

Secondary outcomes

  1. Self-reported Questionnaires

    Hospital Anxiety and Depression Scale (HADS), a self-assessed questionnaire consisting of 14 items (0-3 Likert scale) assessing symptoms of depression (HADS-D subscale) and anxiety (HADS-A subscale).

    Time frame: Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.

  2. Self-reported Questionnaires

    Modified Fatigue Impact Scale (MFIS), with a score range of 0-84 for each item, with the highest score indicating greater fatigue severity.

    Time frame: Four points in time: pre-treatment, immediately following treatment, 6 months and 18 months after treatment is completed.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 24 months is close to that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2024
First posted
Dec 9, 2024
StartActual
Dec 5, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Aug 2028
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06723444
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Collaborators
Instituto de Saude Publica da Universidade do Porto, Center of Psychology at University of Porto
Responsible party
Márcia Inês Teixeira França (Psychologist, Centro Hospitalar De São João, E.P.E.) — Principal investigator
First posted
Dec 9, 2024
Start date
Dec 5, 2024
Primary completion
Dec 2026 (estimated)
Completion
Aug 2028 (estimated)
Last update
Feb 12, 2025

Study contacts

Márcia França, Master's Degree
Contact
marcia.franca.mf@gmail.com
+351965495454

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion